See why Craig-Hallum Is Bullish On iSpecimen

Craig-Hallum initiated coverage of iSpecimen Inc ISPC with a Buy rating and $20 price target. 

  • "Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens, writes analyst Matthew Hewitt.
  • The analyst notes that though the Company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenue for 2021 on track to be nearly triple the 2019 level.
  • Related: iSpecimen Stock Rallies On Supply Pact Of Human Biospecimens For COVID-19 Research.
  • The Company offers a range of biofluids, tissue, and stem and immune cells, including specimens with genetic variants (such as COVID-19 variants).
  • Recently, iSpecimen expanded its global supplier network, with 25% of its newest specimen suppliers in 2021 coming from outside the U.S. 
  • Throughout 2021, iSpecimen has added nearly two dozen biospecimen suppliers to its network across the U.S., Europe, and Asia-Pacific.
  • In December, iSpecimen expanded its global biospecimen provider network to support research related to neurological disorders.
  • Price Action: ISPC shares are up 7.20 at $8.64 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Long IdeasNewsHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!